Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences Group (SLS) EBITDA: 2010-2023

Historic EBITDA for SELLAS Life Sciences Group (SLS) over the last 9 years, with Dec 2023 value amounting to -$37.9 million.

  • SELLAS Life Sciences Group's EBITDA rose 13.43% to -$8.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$37.9 million, marking a year-over-year increase of 9.73%. This contributed to the annual value of -$37.9 million for FY2023, which is 9.73% up from last year.
  • Latest data reveals that SELLAS Life Sciences Group reported EBITDA of -$37.9 million as of FY2023, which was up 9.73% from -$42.0 million recorded in FY2022.
  • SELLAS Life Sciences Group's 5-year EBITDA high stood at -$17.0 million for FY2020, and its period low was -$42.0 million during FY2022.
  • In the last 3 years, SELLAS Life Sciences Group's EBITDA had a median value of -$37.9 million in 2023 and averaged -$35.0 million.
  • Per our database at Business Quant, SELLAS Life Sciences Group's EBITDA climbed by 15.26% in 2020 and then plummeted by 65.85% in 2022.
  • SELLAS Life Sciences Group's EBITDA (Yearly) stood at -$20.0 million in 2019, then rose by 15.26% to -$17.0 million in 2020, then plummeted by 48.95% to -$25.3 million in 2021, then plummeted by 65.85% to -$42.0 million in 2022, then climbed by 9.73% to -$37.9 million in 2023.